Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.14M$3.14Mderivedno prior Q4 2023 on file Net Income$17.98M$17.98MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$7,134,000N/M Operating Cash Flowderived-$30,466,000N/M Free Cash Flowderived-$30,607,000N/M Margins · derivedOperating margin-227.5%
Net margin573.4%
ended Dec 31, 2024 · filed Mar 17, 2025 · 76 d after period end